fashion -WSS

fashion

author：fashion 2025-09-29 13:46:22 - browse：32925

MODERNA - Norwood facility — Alex Hogan/STAT

Moderna announced Monday that, in a Phase 3 clinical trial, its combination Covid-19 and influenza vaccine generated stronger immune responses in older adults than individual vaccines that target those viruses.

The findings, disclosed in a press release, suggest the company may be on track to bring a combination flu and Covid vaccine to the market, potentially as early as autumn 2025.

“We’re excited to move forward in our discussions with regulators, and hopefully continue to help address respiratory viruses globally,” Moderna President Stephen Hoge told STAT in an interview in which he acknowledged that the fall 2025 vaccine rollout is a target the company would like to hit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Pharma companies must ensure equitable access to obesity drugs

focus

WSS

Senators start work on Medicare physician payment reform

Cigna wins case to block Amy Bricker's move to CVS

How digital tools helped lower hypertension in marginalized patients

My daughter's legacy lives on through her writing, phage therapy

How digital tools helped lower hypertension in marginalized patients

The Readout: Gilead, Bernie Sanders, and other pharma news

hotspot

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Study: Why relieving medical debt did not improve financial outcomes

In age of alternative facts, a scholarly course on calling out crap

Medical device trials still don't enroll enough women, study finds

Bright Health sells Medicare Advantage business to Molina

A disappointing year of Humira biosimilars

The high cost of giving birth even with insurance

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

FDA approval of Sarepta Duchenne genetic therapy gives me hope

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

explore

The system is set up to fail children with medical complexity

California wildfire smoke linked to 52,000 early deaths, study says

Vaccine advisory panel ACIP left half staffed by HHS

Robert F. Kennedy is pitching centrism on health, even on abortion

The system is set up to fail children with medical complexity

The Readout: Gilead, Bernie Sanders, and other pharma news

leisure time

focus

hotspot

knowledge